Page last updated: 2024-10-28

miltefosine and Breast Neoplasms

miltefosine has been researched along with Breast Neoplasms in 28 studies

miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.

Breast Neoplasms: Tumors or cancer of the human BREAST.

Research Excerpts

ExcerptRelevanceReference
"Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis."9.09Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999)
"To compare 6% miltefosine solution (Miltex; Asta Medica, Frankfurt, Germany), a new topical cytostatic drug, with placebo as palliative treatment for cutaneous metastases from breast cancer."9.09Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. ( David, M; Hardy, J; Houston, S; Leonard, R; Mansi, J; Simmonds, P; van Tienhoven, G, 2001)
"This study describes the molecular signaling involved in the different cell death modes of triple-negative breast cancer cells induced by hexadecylphosphocholine (HePC/miltefosine), a clinically relevant anticancer alkylphosphocholine."7.74Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine). ( Chakrabandhu, K; Huault, S; Hueber, AO, 2008)
"Miltefosine was selected because of its efficacy in breast cancer models."6.69Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. ( Beijnen, JH; Mandjes, IA; Sindermann, H; ten Bokkel Huinink, WW; Terwogt, JM, 1999)
"Miltefosine therapy was discontinued in two patients due to nausea and in one patient due to skin toxicity."6.69Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. ( Bontenbal, M; Planting, AS; Seynaeve, C; Sindermann, H; Smorenburg, CH; Verweij, J, 2000)
"Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis."5.09Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999)
"To compare 6% miltefosine solution (Miltex; Asta Medica, Frankfurt, Germany), a new topical cytostatic drug, with placebo as palliative treatment for cutaneous metastases from breast cancer."5.09Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. ( David, M; Hardy, J; Houston, S; Leonard, R; Mansi, J; Simmonds, P; van Tienhoven, G, 2001)
"This study describes the molecular signaling involved in the different cell death modes of triple-negative breast cancer cells induced by hexadecylphosphocholine (HePC/miltefosine), a clinically relevant anticancer alkylphosphocholine."3.74Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine). ( Chakrabandhu, K; Huault, S; Hueber, AO, 2008)
"Miltefosine (hexadecylphosphocholine) is used for topical treatment of breast cancers."3.71MDR1 causes resistance to the antitumour drug miltefosine. ( Grunicke, H; Hofmann, J; Liu, R; Lu, P; Pietro, AD; Rybczynska, M; Sharom, FJ; Spitaler, M; Steinfels, E, 2001)
"Miltefosine was selected because of its efficacy in breast cancer models."2.69Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. ( Beijnen, JH; Mandjes, IA; Sindermann, H; ten Bokkel Huinink, WW; Terwogt, JM, 1999)
"Miltefosine therapy was discontinued in two patients due to nausea and in one patient due to skin toxicity."2.69Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. ( Bontenbal, M; Planting, AS; Seynaeve, C; Sindermann, H; Smorenburg, CH; Verweij, J, 2000)
"D-19391 was added to the SK-BR-3 breast cancer cell line and HePC to the Molt-4 leukemia cell line in concentrations of, respectively, 18."1.30Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography. ( Brochez, V; De Potter, CR; Diniz, JA; Van den Eeckhout, EG; Van Heuverswyn, D, 1999)
" Conventional non-compartmental pharmacokinetic analysis and an elaborate three- and four-compartmental model were used for explaining the experimental data."1.30Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice. ( Arndt, D; Fahr, A; Fichtner, I; Teppke, AD; Zeisig, R, 1999)
"Suramin has shown antitumour activity in vitro and in vivo."1.29The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. ( Lopez Lopez, R; Peters, GJ; Pinedo, HM; van Rijswijk, RE; Wagstaff, J, 1994)
"Widespread local recurrence of breast cancer, untreatable by surgery or radiation therapy, can present a serious therapeutic problem predominantly in patients refractory to systemic therapy."1.28Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. ( Eibl, H; Hilgard, P; Nagel, G; Peukert, M; Sindermann, H; Unger, C, 1990)
" After oral application He-PC was well absorbed from the intestine and metabolized in the liver by phospholipases C and D."1.28Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. ( Breiser, A; Damenz, W; Eibl, H; Engel, J; Fleer, EA; Hilgard, P; Kim, DJ; Nagel, G; Unger, C, 1989)

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19902 (7.14)18.7374
1990's19 (67.86)18.2507
2000's5 (17.86)29.6817
2010's1 (3.57)24.3611
2020's1 (3.57)2.80

Authors

AuthorsStudies
Jangir, S1
Bala, V1
Lal, N1
Kumar, L1
Sarswat, A1
Kumar, A1
Saini, KS1
Sharma, V1
Verma, V1
Maikhuri, JP1
Konwar, R1
Gupta, G1
Sharma, VL1
El-Sheridy, NA1
El-Moslemany, RM1
Ramadan, AA1
Helmy, MW1
El-Khordagui, LK1
Chakrabandhu, K1
Huault, S1
Hueber, AO1
Lopez Lopez, R1
van Rijswijk, RE1
Wagstaff, J1
Pinedo, HM1
Peters, GJ1
Fichtner, I5
Zeisig, R4
Naundorf, H2
Jungmann, S1
Arndt, D4
Asongwe, G1
Double, JA1
Bibby, MC2
Bruyneel, EA1
Storme, GA1
Schallier, DC1
Van den Berge, DL1
Hilgard, P5
Mareel, MM1
Colombo, DT2
Tran, LK2
Reitz, RC2
Clive, S2
Leonard, RC2
Eue, I1
Sternberg, B1
Safa, O1
Parkin, SM1
Speck, JJ1
Stahn, R1
Terwogt, JM1
Mandjes, IA1
Sindermann, H5
Beijnen, JH1
ten Bokkel Huinink, WW1
Brochez, V1
Van Heuverswyn, D1
Diniz, JA1
De Potter, CR1
Van den Eeckhout, EG1
Gardiner, J1
Teppke, AD1
Fahr, A1
Smorenburg, CH1
Seynaeve, C1
Bontenbal, M1
Planting, AS1
Verweij, J1
Moĭseenko, VM1
Orlova, RV1
Ermakova, NA1
Protsenko, SA1
Rybczynska, M1
Liu, R1
Lu, P1
Sharom, FJ1
Steinfels, E1
Pietro, AD1
Spitaler, M1
Grunicke, H1
Hofmann, J1
Leonard, R1
Hardy, J1
van Tienhoven, G1
Houston, S1
Simmonds, P1
David, M1
Mansi, J1
Haberkorn, U1
Reinhardt, M2
Strauss, LG1
Oberdorfer, F1
Berger, MR2
Altmann, A1
Wallich, R1
Dimitrakopoulou, A1
van Kaick, G1
Unger, C5
Peukert, M3
Engel, J3
Eibl, H5
Rewasowa, EC1
Büttner, B1
Becker, M1
Görlich, M1
Yanapirut, P1
Schmähl, D1
Nagel, G2
Damenz, W1
Fleer, EA1
Kim, DJ1
Breiser, A2
von Heyden, HW1
Nagel, GA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Fluorescent Nanoparticles Conjugated Long-acting Somatostatin Analog for Potent Suppression and Bioimaging Breast Cancer[NCT04138342]Phase 130 participants (Anticipated)Interventional2019-09-15Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for miltefosine and Breast Neoplasms

ArticleYear
Hexadecylphosphocholine: a new and selective antitumor drug.
    Cancer treatment reviews, 1990, Volume: 17, Issue:2-3

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Screening Assays, Antitumor; Female; Humans;

1990

Trials

5 trials available for miltefosine and Breast Neoplasms

ArticleYear
Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
    British journal of cancer, 1999, Volume: 79, Issue:7-8

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dr

1999
Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44 Suppl

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Br

1999
Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.
    Anti-cancer drugs, 2000, Volume: 11, Issue:10

    Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middl

2000
[Treatment with Miltex for metastatic skin lesions in breast cancer] .
    Voprosy onkologii, 2000, Volume: 46, Issue:5

    Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Phosphorylcholine; Skin

2000
Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Do

2001

Other Studies

22 other studies available for miltefosine and Breast Neoplasms

ArticleYear
Novel alkylphospholipid-DTC hybrids as promising agents against endocrine related cancers acting via modulation of Akt-pathway.
    European journal of medicinal chemistry, 2014, Oct-06, Volume: 85

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Ditiocarb; Drug Sc

2014
Enhancing the
    Drug delivery, 2021, Volume: 28, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Chemistry, Pharmaceutica

2021
Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine).
    FEBS letters, 2008, Dec-24, Volume: 582, Issue:30

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Fas Ligand Protein; fas Recept

2008
The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Divisi

1994
Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes.
    Breast cancer research and treatment, 1994, Volume: 32, Issue:3

    Topics: Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response R

1994
Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:14

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Female; Gene Expression Regulation, Neoplast

1993
The effects of hexadecylphosphocholine (HPC) a mixture of alkylphosphocholines (APC) and different dietary oils on the growth of a human mammary tumor.
    Proceedings of the Western Pharmacology Society, 1993, Volume: 36

    Topics: Animals; Breast Neoplasms; Corn Oil; Dietary Fats, Unsaturated; Dinoprostone; Fish Oils; Humans; Mic

1993
Miltefosine in recurrent cutaneous breast cancer.
    Lancet (London, England), 1997, Mar-01, Volume: 349, Issue:9052

    Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Phosphorylcholi

1997
Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas.
    Breast cancer research and treatment, 1997, Volume: 43, Issue:3

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Cholesterol; Ethanol

1997
IL-1 gene expression in human mammary tumour xenografts after treatment with hexadecylphosphocholine.
    Biochemical Society transactions, 1997, Volume: 25, Issue:2

    Topics: Animals; Antigens, CD; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Gene Expre

1997
Comparison of hexadecylphosphocholine with fish oil as an antitumor agent.
    Journal of lipid mediators and cell signalling, 1997, Volume: 17, Issue:1

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Dinoprostone; Docosahexaenoic Acids; Drug Combinat

1997
Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid.
    Biochimica et biophysica acta, 1998, Nov-11, Volume: 1414, Issue:1-2

    Topics: Animals; Breast Neoplasms; Cell Division; Female; Humans; Liposomes; Metallothionein 3; Mice; Mice,

1998
Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography.
    Lipids, 1999, Volume: 34, Issue:5

    Topics: Antineoplastic Agents; Breast Neoplasms; Chromatography, Gas; Humans; Leukemia; Phosphorylcholine; R

1999
Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice.
    Breast cancer research and treatment, 1999, Volume: 58, Issue:1

    Topics: Animals; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Chemistry, Pharmaceutical; Disea

1999
MDR1 causes resistance to the antitumour drug miltefosine.
    British journal of cancer, 2001, May-18, Volume: 84, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Ca

2001
Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1992, Volume: 33, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatogra

1992
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
    Progress in experimental tumor research, 1992, Volume: 34

    Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms;

1992
Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives.
    Breast cancer research and treatment, 1992, Volume: 23, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Drug Screening Assays, A

1992
In vitro investigations on the antineoplastic effect of hexadecylphosphocholine.
    Arzneimittel-Forschung, 1991, Volume: 41, Issue:6

    Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Breast Neoplasms; Colony-Forming Units Assay; Hum

1991
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
    Cancer treatment reviews, 1990, Volume: 17, Issue:2-3

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dr

1990
Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
    Acta oncologica (Stockholm, Sweden), 1989, Volume: 28, Issue:2

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Choline; Drug Screening Assays, Antitumor; Female;

1989
Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.
    Onkologie, 1988, Volume: 11, Issue:6

    Topics: Administration, Topical; Breast Neoplasms; Choline; Drug Evaluation; Female; Humans; Neoplasm Recurr

1988